A Case of Long-term Survival with Autologous Recovery after Double Cord Blood Transplantation for Juvenile Myelomonocytic Leukemia
10.15264/cpho.2015.22.2.186
- Author:
Hyoung Jin LEE
1
;
Jung Yoon CHOI
;
Che Ry HONG
;
Ji Won LEE
;
Hyoung Jin KANG
;
Kyung Duk PARK
;
Hee Young SHIN
;
Hyo Seop AHN
Author Information
1. Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. kanghj@snu.ac.kr
- Publication Type:Case Report
- Keywords:
Juvenile myelomonocytic leukemia;
Doule cord blood transplantation;
Autologous recovery;
Outcome
- MeSH:
Anemia;
Blood Cell Count;
Bone Marrow;
Bone Marrow Examination;
Chimerism;
Cytarabine;
Drug Therapy;
Etoposide;
Fetal Blood;
Fetal Hemoglobin;
Humans;
Incidental Findings;
Isotretinoin;
Leukemia, Myelomonocytic, Juvenile;
Male;
Monocytes;
Recurrence;
Seoul;
Skin;
Thrombocytopenia;
Vincristine
- From:Clinical Pediatric Hematology-Oncology
2015;22(2):186-189
- CountryRepublic of Korea
- Language:English
-
Abstract:
A 1.1 year old boy was admitted to the Seoul National University Children's Hospital because of incidental findings of hepatosplenomegaly, skin lesion and multiple intra- abdominal lymphadenopathies. Anemia and thrombocytopenia were found based on the initial complete blood count (CBC) measurements. Because of bicytopenia and hepatosplenomegaly, bone marrow examination was performed which revealed hypercellular marrow with increased monocytes and granulopoiesis. The hemoglobin F level was high for his age, and monocyte production was increased. The patient was diagnosed with juvenile myelomonocytic leukemia at the age of 1.2 years. Chemotherapy with cytarabine, etoposide, vincristine, and isotretinoin was initiated. After 6 cycles of chemotherapy, the CBC normalized. He underwent double cord blood transplantation (dCBT), but chimerism studies showed autologous recovery. However, he did not show relapse during the 5 years post-transplant during which he received isotretinoin. He is surviving disease-free 9 years after dCBT.
